John L. Mee

Cognigenics, Inc. is a company founded in 2019 that specializes in genetic neuroengineering using patent-pending CRISPR technology to target and modulate neural circuits responsible for mental health disorders such as anxiety, depression, ADHD, and cognitive impairment. The company is based in Eagle, ID. Cognigenics is revolutionizing the treatment of mental health conditions through their innovative technology. The company was founded by John L. Mee, Dean Radin, and Barry J. Linder, with John L. Mee serving as CEO since incorporation.

Cognigenics, Inc. is a company founded in 2019 that specializes in genetic neuroengineering using patent-pending CRISPR technology to target and modulate neural circuits responsible for mental health disorders such as anxiety, depression, ADHD, and cognitive impairment. The company is based in Eagle, ID. Cognigenics is revolutionizing the treatment of mental health conditions through their innovative technology. The company was founded by John L. Mee, Dean Radin, and Barry J. Linder, with John L. Mee serving as CEO since incorporation.

Cognigenics, Inc. is a company founded in 2019 that specializes in genetic neuroengineering using patent-pending CRISPR technology to target and modulate neural circuits responsible for mental health disorders such as anxiety, depression, ADHD, and cognitive impairment. The company is based in Eagle, ID. Cognigenics is revolutionizing the treatment of mental health conditions through their innovative technology. The company was founded by John L. Mee, Dean Radin, and Barry J. Linder, with John L. Mee serving as CEO since incorporation.